{"links":{"feed":"https://www.erudio.com/reports/fight-101-nct02393248/feed.json","html":"https://www.erudio.com/reports/fight-101-nct02393248","json":"https://www.erudio.com/reports/fight-101-nct02393248.json","markdown":"https://www.erudio.com/reports/fight-101-nct02393248.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"fight-101-nct02393248"}},"request":"https://www.erudio.com/contact?report=fight-101-nct02393248"},"offer":{"cited_clinicians":8,"cited_commentary_sources":8,"verified_hcp_statements":70,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":8},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"fight-101-nct02393248"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=fight-101-nct02393248","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/fight-101-nct02393248","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 70 verified statements · 14 from 8 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T22:16:13.567992Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":9},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Part 3: Number of Participants With Any TEAE"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":0,"title":"Primary endpoint: EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.primaryOutcomes[4]","source_count":0,"title":"Primary endpoint: Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"outcomesModule.primaryOutcomes[5]","source_count":0,"title":"Primary endpoint: Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2"},{"claim_count":4,"coverage":"discussed","id":"T7","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":3,"coverage":"discussed","id":"T8","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":0,"coverage":"no_commentary_found","id":"T9","registry_field":"armsInterventionsModule.armGroups","source_count":0,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T10","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T11","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":2,"title":"Molecular testing and fusion-detection limitations"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":3,"title":"Alteration-specific readings, co-alterations and resistance"},{"claim_count":3,"coverage":"discussed","id":"A3","source_count":2,"title":"Perceived clinical importance and subsequent development"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":1,"title":"FGFR1-rearranged disease: remission language, durability and response criteria"},{"claim_count":2,"coverage":"discussed","id":"A5","source_count":2,"title":"Pancreatic activity and individualized continuation after progression"},{"claim_count":1,"coverage":"discussed","id":"A6","source_count":1,"title":"Expression-selected FGFR-inhibitor research"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":1,"cited_clinicians":8,"cited_clinicians_by_role":{"physician":3,"physician, Gastroenterology":1,"physician, Medical oncology":3,"physician, Pathology":1},"cited_physicians":8,"cited_sources":12,"claims_by_expression_type":{"comparison":12,"experience":2,"interpretation":26,"opinion":9,"primary_context":13,"restatement":3,"uncertainty":5},"claims_by_kind":{"objective_result":4,"protocol_statement":3,"publication_statement":47,"source_observation":16},"clinician_statements":14,"evidence_units":66,"findings":6,"organisational_accounts":1,"people_cited":8,"people_identity_verified":8,"people_total":8,"screened_sources":60,"verified_claims":70},"findings_index":[{"cited_clinicians":3,"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":3,"experience":0,"questions":3,"restated":1,"views":6},"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":3,"passages":9,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"FGFR: most clinicians contrast classes; one weighs amplification as resistance","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-fd8fcf4ba0f7c4698387"],"clause":"one weighs amplification as resistance","holders":1},"cited_claim_ids":["claim-214d46e2adba371ce72d","claim-95f98fb690df02838bc9"],"clinicians":true,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"13 statements from 3 speakers in 4 sources","holder_line":"2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 3 holds its caveat, “one weighs amplification as resistance”"},{"cited_clinicians":3,"id":"F2","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":4},"limitations":3,"links":{"context":0,"support":4},"ma_question":true,"named_voices":3,"passages":4,"sources":3,"sources_by_kind":{"commentary":2,"publication":1}},"title":"Molecular testing: clinicians stress it; one flags unknown-partner gaps","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-dc828b30dee493df6e7c"],"clause":"one flags unknown-partner gaps","holders":1},"cited_claim_ids":["claim-d28a9168415ca99ab5c6","claim-66a2cf9a24acf8b046b3","claim-dc828b30dee493df6e7c"],"clinicians":true,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"4 statements from 3 speakers in 3 sources","holder_line":"3 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags unknown-partner gaps”"},{"cited_clinicians":2,"id":"F3","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":0,"views":1},"limitations":3,"links":{"context":0,"support":3},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"publication":1}},"title":"FGF/FGFR-altered pancreatic cancer: what clinicians note in pemigatinib activity","title_holders":{"cited_claim_ids":["claim-87818502d0381588afff","claim-1eb5131a25ba154128c6"],"clinicians":true,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"3 statements from 2 speakers in 3 sources","holder_line":"2 of the 2 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F4","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":2},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":6,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"FGFR-rearranged M/LN: a clinician highlights a CR; one welcomes approval","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-e95a7210c9d7a728bfba"],"clause":"one welcomes approval","holders":1},"cited_claim_ids":["claim-f8d2e72ebe25849805ce"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"5 statements from 2 speakers in 2 sources","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of the 2 holds its caveat, “one welcomes approval”"},{"cited_clinicians":1,"id":"F9","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":3},"limitations":2,"links":{"context":1,"support":3},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"FIGHT-101: how a clinician recalls confidence from the first patient","title_holders":{"cited_claim_ids":["claim-19d4696a1c2af14a7eae"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"3 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F10","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"High FGF/FGFR expression: a clinician proposes evaluating FGFR inhibitors","title_holders":{"cited_claim_ids":["claim-12eaa82319859797b6e7"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"X accounts distinguish alteration classes; one only tentatively links amplification to resistance"},{"id":"section-2","level":2,"title":"X accounts emphasize molecular testing; one flags missed unknown-partner fusions"},{"id":"section-3","level":2,"title":"One X account describes pancreatic effectiveness; the monotherapy publication explains one continuation after progression"},{"id":"section-4","level":2,"title":"One X account highlights a deep remission; another welcomes pemigatinib approval"},{"id":"section-5","level":2,"title":"A source-described presenter recalls first-patient confidence in FIGHT-101"},{"id":"section-6","level":2,"title":"Beyond the trial population"},{"id":"section-7","level":3,"title":"One X account proposes evaluation in high-expression tumors"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1, phase2","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)"},{"findings":[],"id":"T2","label":"Primary endpoint: Part 3: Number of Participants With Any TEAE"},{"findings":[],"id":"T3","label":"Primary endpoint: E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2"},{"findings":[],"id":"T4","label":"Primary endpoint: EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2"},{"findings":[],"id":"T5","label":"Primary endpoint: Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2"},{"findings":[],"id":"T6","label":"Primary endpoint: Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T7","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T8","label":"Population and setting"},{"findings":[],"id":"T9","label":"The comparison"},{"findings":[],"id":"T10","label":"Safety and tolerability"},{"findings":[],"id":"T11","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T22:16:13.567992Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T22:27:18Z","record_hash":"15eeb709f7981936327fde25676b4bd2debf7e6ad180c5b61d3cc99770762955","release_hash":"082adf189b7f49986f351e8f87963c21fe6efc48ce15445525ddfd41b63fd077","report_id":"erudio-nct02393248","run_id":"c8599240-0dc3-4b63-a196-07b5925b8f89","schema_version":"5.0","slug":"fight-101-nct02393248","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"In discussing FIGHT-101, a gastroenterologist finds the mutation results less conclusive, while expressing broader confidence in FGFR inhibitors for fusions. A medical oncologist tentatively suggests that FGFR amplification might signal resistance. Patient selection also raises a testing concern: a physician warns that some routine panels miss fusions with unknown partners. These views do not establish a difference in benefit between alteration groups or validate amplification as a resistance mechanism.","examples":[],"meta_description":"60 sources screened · 70 verified statements (14 from clinicians verified by NPI or staff page) from 12 sources · 6 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T22:27:18Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":60},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","53 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 3 sources about other trials or topics are not included.","ClinicalTrials.gov first posted results for the trial on 6 January 2023. The cited X discussion spans May 2022 to July 2026 and includes comments both before and after that posting.","The named X authors' cited statements do not provide detailed assessments of dose selection, schedule-dependent tolerability or individual combinations. The results publications discuss those topics, but their judgments cannot be treated as the named authors' practical views.","Reposts do not establish independent agreement. Views from a person described in the source as presenting FIGHT-101 and authoring its results are not counted as independent external endorsements.","Individual responses and small, heterogeneous molecular or combination groups do not support tumor-wide efficacy claims, efficacy equivalence between doses or rankings between regimens.","Only some potentially relevant regulatory documents were reviewed. Approval comments are presented as attributed reactions, not as a comprehensive assessment of indications or regulatory history."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":3,"registry":1,"regulatory":0,"x_thread":8,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":8,"context":1,"methods":1,"results":2},"count":12,"evidence_window":{"end":"2026-07-25","start":"2022-05-16"},"retrieval_snapshot":"2026-11-21T21:11:57.531137Z","timeline":[{"count":2,"week":"2022-W20"},{"count":1,"week":"2022-W27"},{"count":1,"week":"2022-W34"},{"count":1,"week":"2022-W36"},{"count":1,"week":"2022-W39"},{"count":1,"week":"2022-W42"},{"count":1,"week":"2022-W45"},{"count":1,"week":"2026-W30"}],"undated_sources":4},"quote_policies":[{"id":"clinicaltrials:NCT02393248:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02393248:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02393248:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02393248:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02393248:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:34951522","quote_policy":"short_quote_link_out"},{"id":"pubmed:35176457","quote_policy":"no_derivatives"},{"id":"pubmed:38986210","quote_policy":"no_derivatives"},{"id":"openfda:9e1f2222-1d89-4e63-989c-ccebe2ab1eb4:20260609","quote_policy":"short_quote_link_out"},{"id":"openfda:3aef8dbc-34d0-4150-89f0-3b16cf0fbfdb:20261026","quote_policy":"short_quote_link_out"},{"id":"openfda:9333c79b-d487-4538-a9f0-71b91a02b287:20261016","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mypivy5t57wtunwgd3r3e2ub-3m4stjfmbn22o","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1140964839143223296:0e91d207-de9c-4d07-ab51-a3a983878ef5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1252281223688396803:3520de82-4dc9-4cc0-a7d9-142b9117f7f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1261055456937639938:342a193c-507c-480a-a18f-7269d433262a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1266766218649833472:f3c6aa00-5c4c-4b07-b5fa-9f123507a5dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1267111502525296640:507578c5-1e50-4eb6-84da-f016ed50a3e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1272144270611361792:2ab4cd11-0e41-4023-9fa5-2af498ef217f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1351863738979262464:6fc69948-cd18-4bab-80ac-1250d9f26c4b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1493371129637240835:a232633e-3e4e-4b3f-a3d6-db3e880c5230","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1493372267048407043:95112430-fd5c-42bc-a79f-cdf0d089338d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1493373269361242113:65c8d096-f4c1-452b-86a5-4f1f632f4fbb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1493762056448876544:fd7587ed-ffcc-40db-b8b2-493c8a1ce220","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1493925629355433989:0189f0be-8b4e-4c22-9f67-5a84e21945e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1494550899011866640:cccccf54-eba9-48b5-b77c-c8a929e6dcea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1494552941469913088:5b3e6fe6-cfda-499e-a84b-4838e8ca056e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1494554166215118849:936534c8-d8fc-431a-9dea-b93a988b633e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1495399404089626634:f04f434c-fc7f-4296-8c5f-c5d5c572377b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1495407631225270275:5b543d46-5d94-4137-9257-3ff0d9f867a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1496473807841894403:985d9d94-0632-4584-bef1-77e4450fa36d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1496475795799396355:9ff37742-39fa-4584-b62e-d810f72aa502","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1499388228146765825:ed8f78ed-f990-464a-9443-f67c0b358f5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1500352615300882433:331a444a-24f6-449a-a3f6-2ec32e072e6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1505219894517780480:b40fe54a-d35c-4076-a3f0-29a23ef6b8dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1507793325507678211:c63e3cfc-e2a2-45bc-b19e-b4d51a670117","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1509555214554173442:d2c9003c-3d49-43b0-8a38-19e19c4ed38c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1510041615162773510:43639203-a2fc-438b-acac-86269e16b932","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1511843560827588609:65cd48cd-b1fb-4727-a0c7-be160cf3a572","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1513871244122378260:a63f76aa-3cb2-4f1f-a782-a5d2207a2627","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1516035078828306438:5570566e-fafd-4bb1-bd4a-e80d8acf4926","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1516256244129968133:3121062f-9b49-420b-9dac-4593b6a14262","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1518597150619414528:5ab5e60d-2f04-460b-8ded-ba3deb026c3d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1518598174843232257:ef104f3a-b1a0-4df8-b0f5-b545363671d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1519708888010010626:385f2051-c81a-4338-83f3-68d9b8321da0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1526154017772081153:1b5941e8-9d0f-46cb-85bb-66a9b816b313","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1527390637678481408:f0e5ea8d-b6d6-4113-8754-09e8c08fd044","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1530914147579441153:9d636d82-569e-49e1-8245-f19a15d6f2dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1536368356596531201:e0072638-10e8-4fbe-a642-97322d93c49c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1539494546752647170:bdcfdaa4-55aa-4ed5-bfe3-df2024ff17b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1543232305522769923:16996fda-23c8-4a62-a19a-ef1955f8fb3c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1543238081817579521:5b09d777-bd66-4492-b453-0f600bbb4ada","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1545411589192425472:f70335ce-a7aa-4e6f-a3a9-92948682dfba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1545671545544122374:80c61a1b-39ab-45af-9d33-d4c4edb3d134","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1545830178080841728:9f3494fc-a593-4f70-9755-852ddfb37b86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1563861955701522432:8e437168-1fdd-4c8d-bc8d-8eeb25c8f36f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1576266693860814848:d5cad454-4e36-48f3-8015-6d02841637b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1576267158489018368:83b2d5f9-8924-47ae-b16c-a3bce3ad863e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1576323333146042371:f9ce27e7-036d-4e3b-b8d7-e68ecc8b396f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1582128763009404928:ee918f71-0378-4153-97c1-cfced8cfc301","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1583439645496332288:935b8dcd-db09-4c51-80a8-3fe4659369fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1591444783398268929:2dc4a955-f98e-4947-9a9d-6d135094f919","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1602825431950188545:566dd111-76f5-4bdc-9841-fde58e46174f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1609186673216077824:626eeb5c-4148-44e8-8ea7-fc19a2b50aed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1627044970459979782:44f27895-38c5-4cc1-b5b3-99d942621b39","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1642332195359531008:7f86c90b-3bcd-49dc-9b48-3d09cddfe1c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1642348861145612289:88553c60-869b-461b-831f-4030adfa960c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725989884823826590:42ff2979-8fa5-4f5a-91e9-eca63e86b4b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725990403604627957:b6cf1799-868c-4c49-831c-3db67768a3df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833484897232535738:99fd37b9-030c-4848-885f-d3deb7f654fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1985728408374886615:c3e9afdc-6305-4b44-a100-23cd9e734e3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080839766895980961:b206fcf3-f0cd-4773-8eea-238430456dd7","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":59,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":60},"count":60,"evidence_window":{"end":"2026-07-25","start":"2019-06-18"},"retrieval_snapshot":"2026-11-21T21:11:57.531137Z","timeline":[{"count":1,"week":"2019-W25"},{"count":1,"week":"2020-W17"},{"count":1,"week":"2020-W20"},{"count":2,"week":"2020-W22"},{"count":1,"week":"2020-W24"},{"count":1,"week":"2021-W03"},{"count":10,"week":"2022-W07"},{"count":2,"week":"2022-W08"},{"count":2,"week":"2022-W09"},{"count":1,"week":"2022-W11"},{"count":1,"week":"2022-W12"},{"count":2,"week":"2022-W13"},{"count":1,"week":"2022-W14"},{"count":1,"week":"2022-W15"},{"count":2,"week":"2022-W16"},{"count":3,"week":"2022-W17"},{"count":2,"week":"2022-W20"},{"count":1,"week":"2022-W21"},{"count":1,"week":"2022-W24"},{"count":1,"week":"2022-W25"},{"count":2,"week":"2022-W26"},{"count":3,"week":"2022-W27"},{"count":1,"week":"2022-W34"},{"count":1,"week":"2022-W36"},{"count":3,"week":"2022-W39"},{"count":2,"week":"2022-W42"},{"count":1,"week":"2022-W45"},{"count":1,"week":"2022-W50"},{"count":1,"week":"2022-W52"},{"count":1,"week":"2023-W07"},{"count":2,"week":"2023-W13"},{"count":2,"week":"2023-W46"},{"count":1,"week":"2024-W37"},{"count":2,"week":"2025-W45"},{"count":1,"week":"2026-W30"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":54,"registry":2,"regulatory":0,"x_thread":14,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Pemazyre"],"label":"pemigatinib","slug":"pemigatinib"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"},{"brand_names":["Herceptin"],"label":"trastuzumab","slug":"trastuzumab"},{"brand_names":["Zynyz"],"label":"retifanlimab","slug":"retifanlimab"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"}],"indications":[{"reason":"Unmapped registry condition: Lung Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Solid Tumor","status":"unmapped"},{"reason":"Unmapped registry condition: Gastric Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Urothelial carcinoma","slug":"urothelial-carcinoma"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Endometrial cancer","slug":"endometrial-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"},{"reason":"Unmapped registry condition: Myeloproliferative Neoplasms","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Biliary tract cancer","slug":"biliary-tract-cancer"},{"reason":"Unmapped registry condition: UC","status":"unmapped"},{"reason":"Unmapped registry condition: MPN","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"FIGHT-101","aliases":["FIGHT-101","Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)"],"brief_title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Lung Cancer","Solid Tumor","Gastric Cancer","Urothelial Cancer","Endometrial Cancer","Multiple Myeloma","Myeloproliferative Neoplasms","Breast Cancer","Cholangiocarcinoma","UC","MPN"],"display_condition":"advanced malignancies","display_interventions":[["pemigatinib"]],"enrollment":{"count":201,"type":"ACTUAL"},"interventions":[{"name":"Pemigatinib","synonyms":["INCB054828"],"type":"DRUG"},{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Docetaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Trastuzumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Retifanlimab","synonyms":["INCMGA00012"],"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT02393248","official_title":"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)","overall_status":"TERMINATED","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2021-12-17","type":"ACTUAL"},"primary_endpoints":[{"description":"Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.","measure":"Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","timeFrame":"up to 763 days"},{"description":"Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after a participant provided informed consent. Abnormal laboratory values or test results that occurred after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). TEAEs were defined as adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug and within 30 days of the last dose of study drug.","measure":"Part 3: Number of Participants With Any TEAE","timeFrame":"up to 869 days"},{"description":"E0 was defined as the Baseline serum concentration of phosphate.","measure":"E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2","timeFrame":"predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles"},{"description":"EC50 was defined as the pemigatinib steady-state area under the plasma or serum concentration-time curve that increases 50% of serum phosphate.","measure":"EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2","timeFrame":"predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles"},{"description":"Emax was defined as the maximum degree of increasing of serum phosphate by pemigatinib.","measure":"Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2","timeFrame":"predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles"},{"description":"Serum phosphate concentration was assessed throughout Parts 1 and 2.","measure":"Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2","timeFrame":"predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles"}],"registered_date":{"date":"2015-03-19","type":"ESTIMATED"},"registry_last_updated":"2023-01-06","registry_url":"https://clinicaltrials.gov/study/NCT02393248","short_name":"FIGHT-101","short_name_basis":"canonical_name","sponsor":"Incyte Corporation","start_date":{"date":"2015-02-27","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1, phase2","study_ids":[{"id":"INCB 54828-101","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}